Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01831726 · OUTCOME

Progression-Free Survival (PFS)

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib · Source last updated 2017-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
36 months

What was measured

Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause.

Analysis population: Full Analysis Set (FAS) included all patients who received at least one dose of study drug. FAS was used for the analysis of efficacy endpoints.

Groups in this outcome

TKI258

Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TKI25880

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
TKI2582.4Not reported1.83.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.8
        upper Limit
        3.7
        value
        2.4
denoms
  1. counts
    1. group Id
      OG000
      value
      80
    units
    Participants
description
Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
    id
    OG000
    title
    TKI258
param Type
MEDIAN
population Description
Full Analysis Set (FAS) included all patients who received at least one dose of study drug. FAS was used for the analysis of efficacy endpoints.
reporting Status
POSTED
time Frame
36 months
title
Progression-Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice